EQS-News: Redcare Pharmacy N.V.
/ Key word(s): Miscellaneous
SHOP APOTHEKE EUROPE PROMOTED TO THE MDAX. Sevenum, the Netherlands, 6 June 2023. SHOP APOTHEKE EUROPE will be promoted to the MDAX, the leading German stock index for mid-sized companies, following the latest index review by global index provider STOXX Ltd. Effective 19 June 2023, SHOP APOTHEKE EUROPE will be among the 50 largest listed companies in Germany based on free float market capitalisation, just behind the top 40 companies in the DAX. Jasper Eenhorst, CFO of SHOP APOTHEKE EUROPE, commented on the promotion to the MDAX: "The inclusion in the MDAX is a testament to our sustainable growth strategy and the tireless efforts of our teams. We are excited about the further strengthening of our position in the capital market and look forward to continued success."
SHOP APOTHEKE EUROPE is the leading and fast-growing online pharmacy in Europe, currently operating in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland. Headquartered in the Dutch logistics hub of Sevenum near Venlo with locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven, SHOP APOTHEKE EUROPE offers its customers a broad range of more than 150,000 products at attractive prices: OTC, beauty and personal care products, prescription drugs, high quality natural food and health products, low carb products and sports nutrition as well as other healthcare-related assortments. Currently, around 10 million active customers trust SHOP APOTHEKE EUROPE. Since safe and reliable pharmaceutical advice are top priorities at SHOP APOTHEKE EUROPE, the e-pharmacy provides comprehensive pharmaceutical consulting services. In preparation for the full introduction of the electronic prescriptions in Germany, the company is continuously expanding in the area of digital health services. SHOP APOTHEKE EUROPE (Redcare Pharmacy N.V.) has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and is part of the SDAX stock index.
06.06.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Redcare Pharmacy N.V. |
Erik de Rodeweg 11-13 | |
5975 WD Sevenum | |
Netherlands | |
Phone: | 0800 - 200 800 300 |
Fax: | 0800 - 90 70 90 20 |
E-mail: | Investor.Relations@shop-apotheke.com |
Internet: | www.shop-apotheke-europe.com |
ISIN: | NL0012044747, DE000A19Y072 |
WKN: | A2AR94, A19Y072 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1649945 |
End of News | EQS News Service |
|
1649945 06.06.2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.